Business
Additional Confirmed Response Reported as Part of Amplia Investor Presentation
HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate to 35%Updated data to be presented at the Life Sciences Virtual Investor Forum Melbourne, Australia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial in metastatic pan
About this update from Amplia Therapeutics Ltd.
[{"type":"text","content":"HIGHLIGHTS","length":10,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"An additional confirmed partial response has been recorded in the ongoing ACCENT trial","length":86,"tagName":"p"}]},{"val":[{"type":"text","content":"This brings the confirmed Objective Response Rate to 35%","length":56,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated data to be presented at the Life Sciences Virtual Investor Forum","length":72,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":214,"olType":false},{"type":"text","content":"Melbourne, Australia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce that an additional confirmed partial response (PR) has been recorded in the ongoing ACCENT trial in metastatic pancreatic cancer. The trial investigates the combination of the Company’s best-in-class FAK inhibitor narmafotinib in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane®).","length":469,"tagName":"p"},{"type":"text","content":"The additional PR brings the confirmed objective response rate (ORR) to 35% (19/55) which compares favourably to the ORR of 23% recorded for gemcitabine and nab-paclitaxel alone in the benchmark MPACT trial upon which ACCENT is based.","length":234,"tagName":"p"},{"type":"text","content":"A presentation outlining the data from the ACCENT trial was presented by Amplia CEO Dr Chris Burns at the Life Sciences Virtual Investor Forum on Thursday December 11 at 3pm US ET (Friday December 12 7am AEDT).","length":210,"tagName":"p"},{"type":"text","content":"This ASX announcement was approved and authorised for release by the CEO of Amplia Therapeutics.","length":96,"tagName":"p"},{"type":"text","content":"About Amplia Therapeutics Limited","length":33,"tagName":"p"},{"type":"text","content":"Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and fol...